Dr. Reddy’s Laboratories Ltd. ADR (NYSE:RDY) does about 1.76M shares in volume on a normal day but saw 1430732 shares change hands in the recent trading day. The company now has a market cap of 12.09B USD. Its current market price is $14.53, marking a decrease of -0.21% compared to the previous close of $14.56. The 52 week high reached by this stock is $16.89 whilst the lowest price level in 52 weeks is $12.26.
Dr. Reddy’s Laboratories Ltd. ADR (RDY) has a 20-day trading average at $15.05 and the current price is -13.98% off the 52-week high compared with 18.52% distance from its 52-week low. The 50-day simple moving average of the closing price is $14.78 and its 200-day simple moving average is $14.43. If we look at the stock’s price movements over the week, volatility stands at 0.98%, which increases to 1.27% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 38.76 to suggest the stock is neutral.
The consensus objective for the share price is $14.65, suggesting that the stock has a potential upside of 0.82% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 05, 2025 when HSBC Securities upgraded the stock to “Buy” and issued a price target of $16.90.
The current price level is -3.46%, -1.67%, and 0.69% away from its SMA20, SMA50, and SMA200 respectively, with the RDY price moving above the 50-day SMA on current market day. Dr. Reddy’s Laboratories Ltd. ADR (RDY) stock is down -1.62% over the week and -10.14% over the past month. Its price is -7.73% year-to-date and -7.98% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at 0 and 69.39 for whole year. Expected sales for next quarter are $92.55B, which analysts say will come at $353.28B for the current fiscal year and next year at $350.37B. In addition, estimates put the company’s current quarterly revenue at an average of $88.27B.
To reach the target analysts have set, the stock logically needs to grow 0.82 percent from here.
Outstanding shares total 834.46M with insiders holding 0.00% of the shares and institutional holders owning 13.85% of the company’s common stock. The company has a return on investment of 16.71% and return on equity of 18.36%. The price to earnings ratio (P/E ratio) amounts to 18.14 while the forward price to earnings ratio is 22.57. The beta has a value of 0.29. Price to book ratio is 3.11 and price to sales ratio is 3.14.
